Passage Bio Inc.

08/11/2022 | Press release | Distributed by Public on 08/11/2022 05:06

Passage Bio Doses First Patient in Global Clinical Trial of PBFT02 Gene Therapy for Frontotemporal Dementia with Granulin Mutations